Loss per share (Tables)

12 Months Ended

Mar. 31, 2026


	As of March 31,
	2026			2025			2024
Net loss attributable to Virax Biolabs Shareholders	$	(5,023,750	)	$	(6,061,247	)	$	(6,733,537	)
Basic and diluted loss per share	$	(12.64	)	$	(40.62	)	$	(83.90	)

Schedule of Diluted Loss Per Share

The Company's basic and dilutive loss per share as of March 31, 2026, 2025, and 2024 are as follows:


	As of March 31,
	2026		2025		2024
Weighted average number of ordinary shares used in basic and diluted loss per share (Ordinary shares)		397,590		149,214		80,257
Weighted average number of ordinary shares and potential ordinary shares used as the denominator in calculating diluted loss per share(1)		397,590		149,214		80,257

(1)

For the years ended March 31, 2026, 2025 and 2024, potential ordinary shares are anti-dilutive, as their inclusion in the diluted loss per share calculation would reduce the loss per share, and hence have been excluded.